Fetcroja, known generically as cefiderocol, is a novel antibiotic that belongs to the cephalosporin class, specifically designed to combat a wide range of difficult-to-treat Gram-negative bacterial infections, including those resistant to conventional antibiotics. Its unique mechanism of action involves using iron to enter bacterial cells, thereby overcoming the resistance mechanisms that many Gram-negative bacteria have developed against other antibiotics. Fetcroja is particularly useful in treating infections in hospital settings, such as pneumonia, bloodstream infections, and complicated urinary tract infections, among patients with limited or no alternative treatment options. Its development is a significant step forward in the ongoing battle against antibiotic-resistant bacteria, offering hope for treating severe and life-threatening infections.